Clinical and biological effects of the umbilical cord-derived mesenchymal stromal cell (UC- MSC) secretome in rheumatoid arthritis: A randomised double-blind placebo-controlled trial

Background Although the management of rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs (DMARDs) has advanced, a considerable proportion of patients never achieve durable remission, highlighting the need for adjunctive therapies that restore immune homeostasis rather than simply inhibit a individual cytokine. The secretome derived from umbilical cord-derived mesenchymal stromal cell (UC-MSC) is a promising cell-free regenerative candidate, however, randomised trials linking validated clinical outcomes with mechanistic immune biomarkers remain scarce. Methods In this investigator-initiated, single-centre, randomised, double-blind, placebo-controlled trial, 40 patients with moderate RA receiving stable background conventional synthetic DMARD (csDMARD) therapy were randomly assigned (1:1) to receive intramuscular UC-MSC secretome (1.5 mL weekly for six weeks) or matched placebo. The primary endpoint was ACR20 response at week 7. Secondary outcomes included ACR50/70 responses, DAS28, pain intensity, functional disability, safety, and serum TNF-α, IL-6, and TGF-β1 levels to characterise treatment-associated immunomodulation. Results Compared with placebo, the adjunctive UC-MSC secretome produced a significantly greater ACR20 response (75.0% vs 15.0%; risk ratio 5.0, absolute risk reduction 60%, number needed to treat 2) and major clinical response (ACR50/70: 65.0% vs 15.0%). DAS28-CRP, pain intensity, and functional disability also improved significantly. On log-scale reanalysis, TNF-α did not differ significantly between groups after adjustment for age, sex, and baseline level (geometric mean ratio [GMR] 1.07, 95% CI 0.82–1.40), with equivalence testing confirming that the difference lay within a prespecified 1.5-fold margin. IL-6 showed a nominal unadjusted increase (GMR 2.05; P = 0.034) that lost significance after adjustment (GMR 1.51; P = 0.216); TGF-β1 did not differ significantly between groups. These findings indicate the UC-MSC secretome therapy may provide a promising cell-free adjunctive treatment for RA, although its underlying biological mechanism remains to be elucidated. Conclusions Adjunctive intramuscular UC-MSC secretome therapy significantly improved ACR20/50 response, DAS28 score, and pain intensity in patients with moderate RA receiving background csDMARD therapy. Larger multicentre trials with longer follow-up and pathway-specific biomarkers are warranted to confirm long-term efficacy and clarify the underlying biological mechanism. Trial registration ClinicalTrials.gov, NCT07715045

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11161817/v1
Primary Topic
Mesenchymal stem cell research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Clinical and biological effects of the umbilical cord-derived mesenchymal stromal cell (UC- MSC) secretome in rheumatoid arthritis: A randomised double-blind placebo-controlled trial

Surya Darma, Muhammad Hanif Ramlee, Muhammad Reagan, Debby Handayati Harahap et al.
Research Square
Mesenchymal stem cell research
preprint

Clinical and biological effects of the umbilical cord-derived mesenchymal stromal cell (UC- MSC) secretome in rheumatoid arthritis: A randomised double-blind placebo-controlled trial

Surya Darma, Muhammad Hanif Ramlee, Muhammad Reagan, Debby Handayati Harahap, Nita Parisa, Aditya Rafrenda, radiyati umi partan, Rudi Erwin Kurniawan, Lidya Ayu Lestari
preprint en

Abstract

Background Although the management of rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs (DMARDs) has advanced, a considerable proportion of patients never achieve durable remission, highlighting the need for adjunctive therapies that restore immune homeostasis rather than simply inhibit a individual cytokine. The secretome derived from umbilical cord-derived mesenchymal stromal cell (UC-MSC) is a promising cell-free regenerative candidate, however, randomised trials linking validated clinical outcomes with mechanistic immune biomarkers remain scarce. Methods In this investigator-initiated, single-centre, randomised, double-blind, placebo-controlled trial, 40 patients with moderate RA receiving stable background conventional synthetic DMARD (csDMARD) therapy were randomly assigned (1:1) to receive intramuscular UC-MSC secretome (1.5 mL weekly for six weeks) or matched placebo. The primary endpoint was ACR20 response at week 7. Secondary outcomes included ACR50/70 responses, DAS28, pain intensity, functional disability, safety, and serum TNF-α, IL-6, and TGF-β1 levels to characterise treatment-associated immunomodulation. Results Compared with placebo, the adjunctive UC-MSC secretome produced a significantly greater ACR20 response (75.0% vs 15.0%; risk ratio 5.0, absolute risk reduction 60%, number needed to treat 2) and major clinical response (ACR50/70: 65.0% vs 15.0%). DAS28-CRP, pain intensity, and functional disability also improved significantly. On log-scale reanalysis, TNF-α did not differ significantly between groups after adjustment for age, sex, and baseline level (geometric mean ratio [GMR] 1.07, 95% CI 0.82–1.40), with equivalence testing confirming that the difference lay within a prespecified 1.5-fold margin. IL-6 showed a nominal unadjusted increase (GMR 2.05; P = 0.034) that lost significance after adjustment (GMR 1.51; P = 0.216); TGF-β1 did not differ significantly between groups. These findings indicate the UC-MSC secretome therapy may provide a promising cell-free adjunctive treatment for RA, although its underlying biological mechanism remains to be elucidated. Conclusions Adjunctive intramuscular UC-MSC secretome therapy significantly improved ACR20/50 response, DAS28 score, and pain intensity in patients with moderate RA receiving background csDMARD therapy. Larger multicentre trials with longer follow-up and pathway-specific biomarkers are warranted to confirm long-term efficacy and clarify the underlying biological mechanism. Trial registration ClinicalTrials.gov, NCT07715045

Research Square
Sriwijaya University (ID), University of Technology Malaysia (MY)
Universitas Sriwijaya
Good health and well-being
Mesenchymal stem cell research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon